Table 1.
Sodium nitroprusside for schizophrenia: Summary of studies included in this meta-analysis.
| Study | Year | Country | Participants | Female sex | Age | Intravenous infusion [μg/(kg·min)] | Follow-up (weeks) | Outcomes | |
|---|---|---|---|---|---|---|---|---|---|
| Intervention/ Control | Sodium nitroprusside | Placebo | |||||||
| Hallak et al. | 2013 | Canada | 10/10 | 3/3 | 25.5 ± 6.7/25.6 ± 3.9 | 0.5 | 0.5 | 4 | PANSS; BPRS-18 |
| Stone et al. | 2016 | Britain | 10/10 | 3/2 | 34 ± 9/40 ± 10 | 0.5 | 0.5 | 4 | PANSS; BPRS-18 |
| Wang et al. | 2018 | China | 21/21 | 10/9 | 30.5 ± 7.3/29.4 ± 7.5 | 0.5 | 0.5 | 4 | PANSS |
| Brown et al. | 2019 | United States | 18/34 | 4/8 | 47.1 ± 10.5/43.0 ± 11.78 | 0.5 | 0.5 | 2 | PANSS |
| Weiser et al. | 2020 | Moldova & Romania | 10/10 | 3/7 | 36.1 ± 5.3/34.5 ± 3.6 | 0.5 | 0.5 | 4 | PANSS |
| Adelino et al. | 2021 | Brazil | 10/10 | 11a | 43.4 ± 8.9a | 0.5 | 0.5 | 4 | PANSS; BPRS-18 |
a
Gender and age in each group were not specified.